Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C.

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...

The U.S. Food and Drug Administration (FDA) has until the end of the month to decide if it will allow OpenBiome, the ...

Opinion: The FDA must act so patients with refractory C. difficile infection can access lifesaving fecal transplants.

Crohn’s disease is a type of inflammatory bowel disease (IBD) that involves periods of remission and flares. Symptoms can ...

Ferring Pharmaceuticals today announced three poster presentations at the American College of Gastroenterology’s annual ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic ...

Symptoms range from mild to severe and can lead to complications such as dehydration, bloody stool, low blood pressure, rapid heart rate and infection in the tissues of the colon. C. diff ...

difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 trials showed a 96% cure rate, positioning it as a potential game-changer with no preexisting resistance and minimal ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff.